Scenarios | Semaglutide 0.5 mg + metformin vs. Sitagliptin 100 mg + metformin | Semaglutide 1 mg + metformin vs. Sitagliptin 100 mg + metformin | ||||
---|---|---|---|---|---|---|
Incremental QALYs | Incremental Costs, ¥ ($) †| ICER | Incremental QALYs | Incremental Costs, ¥ ($) †| ICER | |
Univariate sensitivity analyses | Â | Â | Â | Â | Â | Â |
Time horizon set to be 10 years | 0.04 | –18,169 (–2697) | dominant ‡ | 0.05 | –24,182 (–3589) | dominant § |
Time horizon set to be 20 years | 0.06 | –29,521 (–4382) | dominant ‡ | 0.09 | –41,089 (–6099) | dominant § |
Discount rate (costs and benefits) set to be 0% in line with China guidelines | 0.17 | –64,940 (–9639) | dominant ‡ | 0.25 | –92,752 (–13,768) | dominant § |
Discount rate (costs and benefits) set to be 8% in line with China guidelines | 0.06 | –26,049 (–3867) | dominant ‡ | 0.09 | –35,081 (–5207) | dominant § |
Use UKPDS 68 risk equations to run model | 0.08 | –33,686 (–5000) | dominant ‡ | 0.12 | –46,344 (–6879) | dominant § |
HbA1c threshold for therapy escalation set to be 7.5% | 0.08 | –31,392 (–4660) | dominant ‡ | 0.11 | –35,916 (–5331) | dominant § |
Utility impacts set to be 0.017 per unit BMI decrease and − 0.047 per unit BMI increase [29] | 0.56 | –34,848 (–5173) | dominant ‡ | 0.81 | –48,115 (–7142) | dominant § |
BMI-related costs set to be 0 | 0.08 | 2805 (416) | 34,163 (5071) | 0.12 | 12,125 (1800) | 99,466 (14,764) |
BMI-related costs halved | 0.08 | –16,021 (–2378) | dominant ‡ | 0.12 | –17,995 (–2671) | dominant § |
Alternative utility impacts for vascular complications [27, 28] | 0.08 | –34,848 (–5173) | dominant ‡ | 0.12 | –48,115 (–7142) | dominant § |
Costs of vascular complications halved | 0.08 | –34,662 (–5145) | dominant ‡ | 0.12 | –47,839 (–7101) | dominant § |
Scenario analyses | 0.11 | –37,451 (–5559) | dominant ‡ | 0.15 | –32,841 (–4875) | dominant § |
Probabilistic sensitivity analyses | 0.08 | –33,297 (–4942) | dominant ‡ | 0.12 | –44,632 (–6625) | dominant § |